Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
East Metropolitan Health Service, Australia
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07651618CT.gov A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma | — | Not Yet Recruiting | — | — | — |
NCT06626256CT.gov STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | — | Withdrawn | — | — | — |
NCT04129515CT.gov NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | — | Withdrawn | — | — | — |
NCT04119024CT.gov Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06961786CT.gov TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma | — | Active Not Recruiting | — | — | — |
NCT05669352CT.gov A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases | — | Suspended | — | — | — |
NCT06889766CT.gov NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma | — | Recruiting | — | — | — |
NCT07436390CT.gov IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma | — | Completed | — | — | — |
NCT05913388CT.gov GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | — | Recruiting | — | — | — |
NCT06151847CT.gov Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | — | Completed | — | — | — |
Show 101 more trialsShow fewer
NCT06060613CT.gov Safety and Efficacy of OBX-115 in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05304546CT.gov Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | — | Completed | — | — | — |
NCT04987996CT.gov GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | — | Withdrawn | — | — | — |
NCT05764395CT.gov Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | — | Active Not Recruiting | — | — | — |
NCT04616248CT.gov In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05628883CT.gov Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | — | Completed | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05470283CT.gov Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT05155033CT.gov Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT05361174CT.gov A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | — | Recruiting | — | — | — |
NCT05176470CT.gov Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT05155254CT.gov IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | — | Active Not Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07422779CT.gov Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | — | Recruiting | — | — | — |
NCT04955743CT.gov Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT05034536CT.gov PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT04930783CT.gov NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | — | Active Not Recruiting | — | — | — |
NCT07376317CT.gov Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) | — | Active Not Recruiting | — | — | — |
NCT04697576CT.gov Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | — | Recruiting | — | — | — |
NCT04633902CT.gov Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | — | Unknown | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT05611229CT.gov Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | — | Completed | — | — | — |
NCT04152863CT.gov Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | — | Terminated | — | — | — |
NCT03773744CT.gov MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma | — | Withdrawn | — | — | — |
NCT04007744CT.gov Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03957551CT.gov Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | — | Terminated | — | — | — |
NCT03875079CT.gov A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma | — | Completed | — | — | — |
NCT03474497CT.gov UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | — | Active Not Recruiting | — | — | — |
NCT03645928CT.gov Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03873818CT.gov Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | — | Completed | — | — | — |
NCT03684785CT.gov Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03534635CT.gov Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | — | Unknown | — | — | — |
NCT03265080CT.gov A Study of ADXS-NEO Expressing Personalized Tumor Antigens | — | Terminated | — | — | — |
NCT03475134CT.gov TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) | — | Completed | — | — | — |
NCT03526185CT.gov A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | — | Terminated | — | — | — |
NCT03276832CT.gov Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | — | Completed | — | — | — |
NCT03149029CT.gov Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | — | Active Not Recruiting | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03131908CT.gov Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | — | Active Not Recruiting | — | — | — |
NCT02650986CT.gov Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | — | Active Not Recruiting | — | — | — |
NCT02748564CT.gov Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT02816021CT.gov Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT03021460CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02740920CT.gov Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker | — | Terminated | — | — | — |
NCT02990416CT.gov A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | — | Unknown | — | — | — |
NCT02858869CT.gov Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | — | Completed | — | — | — |
NCT02791594CT.gov Imaging FDG Flare in Melanoma | — | Completed | — | — | — |
NCT02617849CT.gov Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | — | Unknown | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02676869CT.gov Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma | — | Completed | — | — | — |
NCT02625337CT.gov Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients | — | Unknown | — | — | — |
NCT02506153CT.gov Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02521870CT.gov A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | — | Terminated | — | — | — |
NCT02500576CT.gov Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02489266CT.gov In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | — | Withdrawn | — | — | — |
NCT02298959CT.gov Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | — | Active Not Recruiting | — | — | — |
NCT01740557CT.gov Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | — | Completed | — | — | — |
NCT02027935CT.gov CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02306850CT.gov Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | — | Completed | — | — | — |
NCT02354690CT.gov Vemurafenib and TIL Therapy for Metastatic Melanoma | — | Completed | — | — | — |
NCT02379195CT.gov Peginterferon and TIL Therapy for Metastatic Melanoma | — | Completed | — | — | — |
NCT01955460CT.gov Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02278887CT.gov Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02073123CT.gov Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02054520CT.gov Immunotherapy Study for Patients With Stage IV Melanoma | — | Terminated | — | — | — |
NCT01995344CT.gov TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment | — | Terminated | — | — | — |
NCT02062359CT.gov T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | — | Terminated | — | — | — |
NCT01993719CT.gov Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT01807182CT.gov Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT01883323CT.gov Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma | — | Completed | — | — | — |
NCT01701674CT.gov Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | — | Completed | — | — | — |
NCT01833767CT.gov Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | — | Withdrawn | — | — | — |
NCT01659151CT.gov Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | — | Completed | — | — | — |
NCT01339663CT.gov Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT01495572CT.gov Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | — | Terminated | — | — | — |
NCT01468818CT.gov Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT01369875CT.gov Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | — | Terminated | — | — | — |
NCT01369888CT.gov Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | — | Terminated | — | — | — |
NCT01319565CT.gov Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... | — | Completed | — | — | — |
NCT01273181CT.gov MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | — | Terminated | — | — | — |
NCT01218867CT.gov CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | — | Terminated | — | — | — |
NCT01236573CT.gov Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | — | Terminated | — | — | — |
NCT01106235CT.gov Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT01005745CT.gov Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00910650CT.gov Study of Gene Modified Immune Cells in Patients With Advanced Melanoma | — | Completed | — | — | — |
NCT00945269CT.gov Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT00871481CT.gov Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00604136CT.gov Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | — | Unknown | — | — | — |
NCT00670748CT.gov Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | — | Terminated | — | — | — |
NCT00612222CT.gov Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | — | Terminated | — | — | — |
NCT00610311CT.gov Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | — | Terminated | — | — | — |
NCT00553306CT.gov Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | — | Completed | — | — | — |
NCT00924001CT.gov Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | — | Terminated | — | — | — |
NCT00513604CT.gov Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | — | Completed | — | — | — |
NCT00438984CT.gov Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma | — | Completed | — | — | — |
NCT00328861CT.gov Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | — | Completed | — | — | — |
NCT00314106CT.gov Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | — | Completed | — | — | — |
NCT00303836CT.gov Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT00003552CT.gov Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | East Metropolitan Health Service, Australia | P3 | BB · 64 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Therapeutic Autologous Lymphocytes | Fred Hutchinson Cancer Center | P2 | BB |
| Montanide Isa 51 | Ludwig Institute for Cancer Research | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →